fda compounding glp-1 crackdown news today issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA moves to restrict compounded

Conclusion The question of whether the oral GLP-1 pill is available has an answer: yes, it is here, with Rybelsus leading the way

A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes

Policies that require significant coinsurance, deductibles, or lack of caps on annual out-of-pocket spending disproportionately affect these populations

A patient on 2.4 mg of semaglutide weekly might reduce to 1.0 mg or even 0.5 mg for maintenance